title: Protamine neutralization of intravenous and subcutaneous low-molecular-weight heparin (tinzaparin, Logiparin). An experimental investigation in healthy volunteers.
abstract: The aim of the present study was to investigate whether tinzaparin sodium (a low-molecular-weight heparin (LMWH)) was fully and permanently neutralized in vivo in man by protamine sulphate (PS) after intravenous (i.v.) or subcutaneous (s.c.) injection. Fifty healthy adults equally divided in five age- and sex-matched groups were included. The groups received 50 IU unfractionated heparin (UH)/kg body weight (b.w.) i.v., 50 anti-factor Xa (anti-Xa) IU tinzaparin/kg b.w. i.v., 75 anti-Xa IU tinzaparin/kg b.w. s.c., 175 anti-Xa IU tinzaparin/kg b.w. s.c., or 1 ml of saline s.c. PS was given as a 10 min infusion in a dose of 1 mg/100 IU of heparin in the four first groups while 0.5 mg PS/kg b.w. was given in the placebo group. In the i.v. groups PS was administered 45 min after the heparin injection, and in the s.c. groups 180 min post-heparin injection. In the UH group PS fully and permanently neutralized all three activities. In the i.v. tinzaparin group PS reversed 80% of the anti-Xa activity, while the anti-IIa and aPTT activities were fully reversed. A slight, but statistically significant, increase in anti-Xa and anti-IIa activities were seen following i.v. tinzaparin. In the s.c. groups 60-65% of the observed peak anti-Xa activity was neutralized, anti-IIa was almost completely reversed, and aPTT returned nearly to baseline values. A gradual return of the anti-Xa activity (65-75%), anti-IIa activity (55%) and aPTT activity (35-45%) was seen in the s.c. groups 3 h after reversal compared with the observed peak values.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: University of Lund, Department of Surgery, Malmö General Hospital, Sweden.
authors.forename: J
authors.initials: J
authors.lastname: Holst
authors.forename: B
authors.initials: B
authors.lastname: Lindblad
authors.forename: D
authors.initials: D
authors.lastname: Bergqvist
authors.forename: K
authors.initials: K
authors.lastname: Garre
authors.forename: H
authors.initials: H
authors.lastname: Nielsen
authors.forename: U
authors.initials: U
authors.lastname: Hedner
authors.forename: P B
authors.initials: PB
authors.lastname: Ostergaard
mesh_terms: D000293:Adolescent; D000328:Adult; D000990:Antithrombin III / Q000378:metabolism; D005260:Female; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage / Q000037:antagonists & inhibitors*; D006801:Humans; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D010314:Partial Thromboplastin Time; D010919:Placebos; D010976:Platelet Count; D011479:Protamines / Q000008:administration & dosage / Q000494:pharmacology*; D011517:Prothrombin Time; D000078222:Tinzaparin
chemical_list: D006495:Heparin, Low-Molecular-Weight; D010919:Placebos; D011479:Protamines; D000078222:Tinzaparin; D000990:Antithrombin III